Despite recent obstacles, such as product approval denials, changes to treatment recommendations and a challenging economic environment, ongoing adoption of these products continues and overall interest in the use of these products remains high.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the US market across a 10-year period.
Millennium Research Group has up-to-date reports on a wide range of medical device markets worldwide.
* In 2013, Medtronic's INFUSE growth factor product faced continuing revenue declines, while the FDA failed to approve Wright Medical Technology's Augment Bone Graft.
How will growth of the overall BGS market be impacted by ongoing hindrance of its largest revenue segment?
Which BGS product segments will benefit from declining utilization of growth factor products?
* Zimmer's Gel-One product was released into the HA viscosupplementation market in early 2013.
How will its introduction impact the single-injection market?
What does the future look like for the other injection segments?
* The ongoing launch of new nonbone IBDs will impact adoption and thus revenues in the machined bone IBD market.
What factors will drive the uptake of nonbone IBDs, and will the machined bone IBD market be able to maintain some growth through 2022?
Which approaches are most likely to see growth or decline?
* Despite a lack of confidence in the clinical data available for some cell concentration systems, procedure volumes will grow moderately.
Which applications are utilizing these systems the most frequently?
Will the higher cost BMAC systems be able to maintain strong procedure growth during challenging economic times?(The Contents on this Website is a Condensed Version of the Original Report. To View the Complete Version, Please Request a Sample.)
Browse more Biomaterials Market Research Reports